Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.
about
Impact of cardiac magnetic resonance imaging in non-ischemic cardiomyopathiesEvaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusionsMRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and PitfallsLongitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2* in patients with thalassemia major on various chelation regimens: a 6-year study.Semi-automated myocardial segmentation of bright blood multi-gradient echo images improves reproducibility of myocardial contours and T2* determinationEffect of L-type calcium channel blocker (amlodipine) on myocardial iron deposition in patients with thalassaemia with moderate-to-severe myocardial iron deposition: protocol for a randomised, controlled trial.Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overloadReal-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded RatsThe long-term efficacy and tolerability of oral deferasirox for patients with transfusion-dependent β-thalassemia in Taiwan.Treating thalassemia major-related iron overload: the role of deferiprone.Combined chelation therapy with deferasirox and deferoxamine in thalassemia.Validation of a new T2* algorithm and its uncertainty value for cardiac and liver iron load determination from MRI magnitude images.Deferasirox: appraisal of safety and efficacy in long-term therapy.Evaluation of Iron Deposition in the Adrenal Glands of β Thalassemia Major Patients Using 3-Tesla MRI.Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion.A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).Iron chelation therapy in the management of transfusion-related cardiac iron overload.Current approach to iron chelation in children.Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.Clinical pharmacology of deferasirox.Deferasirox nephrotoxicity-the knowns and unknowns.Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).3-Hydroxypyridinone derivatives as metal-sequestering agents for therapeutic use.Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.Deferasirox for managing iron overload in people with thalassaemia.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.Cardiac complications in beta-thalassemia: From mice to men.Deferiprone for the treatment of transfusional iron overload in thalassemia.Current recommendations for chelation for transfusion-dependent thalassemia.The new era of chelation treatments: effectiveness and safety of 10 different regimens for controlling iron overloading in thalassaemia major.Cardiac iron measurement and iron chelation therapy in patients with β thalassaemia major: experience from Taiwan.Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study.Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project.Management of cardiac hemochromatosis.Deferasirox: Over a Decade of Experience in Thalassemia
P2860
Q26765173-2950A5F1-8CD0-4096-AE3B-D48262203C1DQ26765306-CC52771F-38BE-47CB-84DE-A9099A2860E1Q28072173-20E1ECB1-0E34-4507-83BF-FBFD0947E0FDQ33647638-FE78237F-0D92-4B9B-A52E-64669AE697FEQ33715326-48289937-6A50-4576-92E3-02E3B240F4B0Q34692473-6B220819-93DB-417E-8651-864A885C7AF6Q35143774-7B71BAB1-2B43-43C4-A3CF-C4B7100844E8Q35232747-4FC81C0C-1083-45B9-BA2C-6D1EEF7C817DQ35813192-7C273199-0311-480B-90B0-1AA8C65BE9B3Q35906193-5E301D62-0213-42C4-AC33-DC9703444C86Q36080315-F246E55F-EC4A-4CBE-9AAF-206FED938012Q36158835-A5D50CA7-C8D3-4569-9891-3563A480745CQ36344669-6AF46FA0-27C7-49BC-8E6F-CD88AC77B2B4Q36670257-50ABF945-50B0-49DD-A9E7-F07955EBBE4AQ36685024-788AA2F4-61DD-494C-9668-7162D1EA6F8AQ37095523-585AB033-2794-4863-B231-37038F6C8C10Q37410866-2A81F4FC-8125-4B6F-A755-2FFC0CBCDCA4Q37528626-33632B8D-5C9D-4E0D-9370-EDD9BF45A6A2Q37623523-C1DB75DC-D191-4C4F-8E42-96A06FEF4887Q37992181-4004AF65-B37B-4127-B4DF-3A93998A0BF8Q38197269-11685B3B-9DBA-475B-B9ED-06FE8BE711DEQ38219588-27EF0AC7-F0A6-4BE1-A938-400413CEA57DQ38226394-B489D00C-2B04-4340-AC6C-43EBE166BA16Q38232442-2A1B80F2-5A15-4286-A519-A0BD809C85A0Q38388734-98A4C88C-1194-400C-809D-9D53ADAC6A63Q38397352-95495BAA-88D6-46CD-A502-BF922EFCAC27Q38421726-2D0ACC74-A69E-44E2-861D-4F544D0708B4Q38540491-48954F76-BF29-4B21-A65F-1E570B6D500EQ38624033-B3400515-9E11-4F2A-8C31-7C6D97D78BCDQ38650293-4FA4D1DE-E3E6-451F-8345-7503BC658EC7Q38686059-31B5100F-60AB-4AC5-AD2F-FB7487DB532FQ38817259-7E9BBFFF-3176-43FC-8658-E6253AAC2A20Q38836184-5D5F6BA2-DB2E-46A2-9B16-92906356404AQ39260564-0C3418BB-C810-42F9-B97B-BBC0DBF685B4Q44142481-EF071683-D555-4EA2-A3A5-A4A2E5E637D0Q46700826-BF990CAB-EA2E-461E-8780-77106EAA4324Q51877530-E0B5D9DC-75A7-4B11-A663-830AC091C2D6Q55230811-64F91C3F-7EB3-49FD-BE01-118D58FF9CD7Q58701123-502ABE74-DAC0-473A-BC99-0793EAAF91ED
P2860
Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Deferasirox for up to 3 years ...... ents with β-thalassemia major.
@en
Deferasirox for up to 3 years ...... ents with β-thalassemia major.
@nl
type
label
Deferasirox for up to 3 years ...... ents with β-thalassemia major.
@en
Deferasirox for up to 3 years ...... ents with β-thalassemia major.
@nl
prefLabel
Deferasirox for up to 3 years ...... ents with β-thalassemia major.
@en
Deferasirox for up to 3 years ...... ents with β-thalassemia major.
@nl
P2093
P2860
P50
P1433
P1476
Deferasirox for up to 3 years ...... ients with β-thalassemia major
@en
P2093
Amal El-Beshlawy
Antonis Kattamis
Bernard Roubert
Chi-Kong Li
Gabor Domokos
Gillian Smith
Hishamshah Ibrahim
Lee Lee Chan
Mohsen S Elalfy
P2860
P304
P356
10.3324/HAEMATOL.2011.049957
P577
2012-01-22T00:00:00Z